Medgenics (MDGN) Gets Allowance for Key European Patent
Medgenics Inc - MDGN - reported that it has received notice of ‘Intention to Grant’ from the European Patent Office for the patent application entitled “USE OF DERMAL MICRO ORGANS,” with allowed claims covering a core element of its Biopump protein therapy technology. This follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Medgenics’ Intellectual Property Portfolio. Medgenics is developing and commercializing Biopump, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient’s own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

ユーザー：karmastock
再生時間：00:01:13
投稿日時：12/01/22 23:29
カテゴリ：ビジネス全般 
タグ： Amex:MDGN  MDGN  Medgenics  Biopump  Anemia  hemophilia  HCV 

[ 前ページへ戻る ]